Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.15997 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Cailin Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cost-Benefit Analysis, Quality-Adjusted Life Years, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Fujian Provincial Department of Finance, China, Natural Science Foundation of Fujian Province, China, Natural Science Foundation of Fujian Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To examine the cost‐effectiveness of adding finerenone to standard of care (SoC) for treating type 2 diabetes mellitus (T2DM)‐related chronic kidney disease (CKD) in the United States. Materials and Methods Based on the clinical data analysed by FIDELITY, we referenced the validated FINE‐CKD model (Markov model) to evaluate the cost‐effectiveness of SoC versus SoC + finerenone from the perspective of US payers. The model was cycled for 35 years in 4‐month cycles, with cost and utility values derived from the published literature. The primary outcomes were incremental cost‐effectiveness ratio (ICER) and quality‐adjusted life years (QALYs). Deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of the base‐case results.
Results
The treatment strategy of finerenone plus SoC led to gains of 6.95 QALYs and had a lifetime cost of $491 745.31. Compared to SoC, that strategy yielded 0.48 more QALYs at an added cost of $65 305.72. The ICER for finerenone was $135 257.06 per QALY, which is below the willingness‐to‐pay threshold of United States ($150 000/QALY). The results were sensitive to the hazard ratios associated with the efficacy of finerenone and its cost. Probabilistic sensitivity analyses showed that the probability that finerenone plus SoC would be cost‐effective was 57.6%.
Conclusions
For patients with T2DM‐related CKD, adding finerenone to SoC may be a cost‐effective option in the United States. Reasonable price reductions for finerenone could potentially benefit more patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Fujian Medical University, Fuzhou, China.
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
- Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.
ORCID-Profile: Xiaoxia Wei
Förderung
- Fujian Provincial Department of Finance, China
- Natural Science Foundation of Fujian Province, China
- Natural Science Foundation of Fujian Province
Zitieren
APA
Zheng, C., Wu, J., Li, N., Wei, X., Huang, Z., Chen, L., & Chen, Z. (2025). Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15997
Vancouver
Zheng C, Wu J, Li N, Wei X, Huang Z, Chen L, et al. Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.15997
BibTeX
@article{Zheng2025,
author = {Zheng, Cailin and Wu, Jinneng and Li, Na and Wei, Xiaoxia and Huang, Zhixiong and Chen, Lingbin and Chen, Zhou},
title = {Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.15997}
}
EUVIMED